BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37818839)

  • 1. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
    Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
    Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
    Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
    Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
    Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
    Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
    Wang T; Lee K; Rehman A; Daoud SS
    Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
    Foo JB; Saiful Yazan L; Tor YS; Wibowo A; Ismail N; Armania N; Cheah YK; Abdullah R
    J Ethnopharmacol; 2016 Jul; 187():195-204. PubMed ID: 27131434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis.
    Zhu X; Wang K; Zhang K; Zhang T; Yin Y; Xu F
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27879682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines.
    Jafari S; Dabiri S; Mehdizadeh Aghdam E; Fathi E; Saeedi N; Montazersaheb S; Farahzadi R
    Clin Transl Oncol; 2023 Aug; 25(8):2559-2568. PubMed ID: 36964888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
    Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    Simon M; Mesmar F; Helguero L; Williams C
    PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
    Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
    Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
    Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
    Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
    Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
    O'Grady S; Crown J; Duffy MJ
    Med Oncol; 2022 Jul; 39(10):142. PubMed ID: 35834073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
    Zhao Y; Zhou K; Xia X; Guo Y; Tao L
    Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.
    Messina RL; Sanfilippo M; Vella V; Pandini G; Vigneri P; Nicolosi ML; Gianì F; Vigneri R; Frasca F
    Int J Cancer; 2012 May; 130(10):2259-70. PubMed ID: 21647879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.